We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
Read MoreHide Full Article
Prestige Consumer (PBH - Free Report) has witnessed strong momentum in the past year. Shares of the company have risen 17.1% compared with 7.1% growth of the industry during the same time frame. The S&P 500 composite has increased 10.5%.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Prestige Consumer develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare and household cleaning products in the United States, Canada, Australia and certain other international markets. Also, it operates through the e-commerce channel.
The company reports operating results under two segments — North American OTC Healthcare and International OTC Healthcare. Some of the major brands under North American and International OTC Healthcare are BC and Goody's, Chloraseptic, Compound W, Debrox, Dramamine, Fess, Fleet, Hydralyte, Monistat, Nix and Summer's Eve, among others.
Factors Favoring PBH’s Share Price Growth
Prestige Consumer’s share price is trending upward, prompted by its diverse portfolio of well-recognized consumer brands. The company’s core brands together generated nearly 58.6% of the total revenues in fiscal 2024. Its gastrointestinal (GI) product category represents almost one-fifth of all North American sales.
The Eye & Ear Care category consists of a wide range of leading brands. Furthermore, PBH is experiencing impressive growth in the e-commerce channel, continuing its long-term trend of increasing online purchases. This optimism, driven by a solid fiscal 2025 third-quarter performance and increasing revenues from all reportable business segments, is expected to contribute further.
Investors showed optimism about Prestige Consumer’s strategic acquisitions. The company acquired Hydralyte (an over-the-counter oral rehydration brand in Australia) from the Hydration Pharmaceuticals Trust of Victoria, Australia.
PBH’s emphasis on brand building and product innovation looks encouraging. The long-term brand-building initiatives, combined with efficient marketing, channel development and innovative approaches, have enabled its brands to consistently maintain a leading market share position.
The company’s iconic franchise, Dramamine within GI, has been successfully using numerous brand-building tactics to grow with consumers. The most recent innovation includes Dramamine Advanced Herbals, which features ingredients specifically designed to help consumers manage nausea and stress.
Another one within GI is the Fleet brand, a clear market leader with a 100-plus-year history since its creation. Currently, this brand holds over 50% share of the rectal laxative category. It is currently focusing on expanding into adjacent categories, such as oral laxatives. Further, Prestige Consumer is making progress in its women's health franchise, which is represented by two distinct leading market share brands — Monistat and Summers Eve.
Image Source: Zacks Investment Research
Factors That May Offset PODD’s Gains
In the past few years, global economic conditions have been volatile due to factors like supply-chain constraints, rising interest rates, a high inflationary environment and geopolitical events. As a result, in the first nine months of fiscal 2025, the net gross margin was down slightly year over year. Additionally, general and administrative expenses were up 9.6% from the year-ago period’s level.
Furthermore, fluctuating foreign exchange rates remain a concern for Prestige Consumer, as it generates a substantial amount of its total revenues from international business. This could result in unfavorable price increases for the company’s products or lead to higher costs for certain products purchased from its foreign third-party manufacturers.
A Look at PBH’s Estimates
The Zacks Consensus Estimate for fiscal 2025 EPS has moved north 0.4% to $4.52 in the past 30 days.
Prestige Consumer has an earnings yield of 5.3% compared with the industry’s 0.3%.
Phibro Animal Health has an earnings yield of 8.2%, well ahead of the industry’s 1.2%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 27.06%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
Masimo, presently carrying a Zacks Rank #1, has an earnings yield of 2.5%, well ahead of the industry’s -3.6%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 14.4%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term earnings growth rate of 10.7% compared with the industry’s 9.4%. Shares of the company have rallied 12.1% against the industry’s 2.3% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
Prestige Consumer (PBH - Free Report) has witnessed strong momentum in the past year. Shares of the company have risen 17.1% compared with 7.1% growth of the industry during the same time frame. The S&P 500 composite has increased 10.5%.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Prestige Consumer develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare and household cleaning products in the United States, Canada, Australia and certain other international markets. Also, it operates through the e-commerce channel.
The company reports operating results under two segments — North American OTC Healthcare and International OTC Healthcare. Some of the major brands under North American and International OTC Healthcare are BC and Goody's, Chloraseptic, Compound W, Debrox, Dramamine, Fess, Fleet, Hydralyte, Monistat, Nix and Summer's Eve, among others.
Factors Favoring PBH’s Share Price Growth
Prestige Consumer’s share price is trending upward, prompted by its diverse portfolio of well-recognized consumer brands. The company’s core brands together generated nearly 58.6% of the total revenues in fiscal 2024. Its gastrointestinal (GI) product category represents almost one-fifth of all North American sales.
The Eye & Ear Care category consists of a wide range of leading brands. Furthermore, PBH is experiencing impressive growth in the e-commerce channel, continuing its long-term trend of increasing online purchases. This optimism, driven by a solid fiscal 2025 third-quarter performance and increasing revenues from all reportable business segments, is expected to contribute further.
Investors showed optimism about Prestige Consumer’s strategic acquisitions. The company acquired Hydralyte (an over-the-counter oral rehydration brand in Australia) from the Hydration Pharmaceuticals Trust of Victoria, Australia.
PBH’s emphasis on brand building and product innovation looks encouraging. The long-term brand-building initiatives, combined with efficient marketing, channel development and innovative approaches, have enabled its brands to consistently maintain a leading market share position.
The company’s iconic franchise, Dramamine within GI, has been successfully using numerous brand-building tactics to grow with consumers. The most recent innovation includes Dramamine Advanced Herbals, which features ingredients specifically designed to help consumers manage nausea and stress.
Another one within GI is the Fleet brand, a clear market leader with a 100-plus-year history since its creation. Currently, this brand holds over 50% share of the rectal laxative category. It is currently focusing on expanding into adjacent categories, such as oral laxatives. Further, Prestige Consumer is making progress in its women's health franchise, which is represented by two distinct leading market share brands — Monistat and Summers Eve.
Image Source: Zacks Investment Research
Factors That May Offset PODD’s Gains
In the past few years, global economic conditions have been volatile due to factors like supply-chain constraints, rising interest rates, a high inflationary environment and geopolitical events. As a result, in the first nine months of fiscal 2025, the net gross margin was down slightly year over year. Additionally, general and administrative expenses were up 9.6% from the year-ago period’s level.
Furthermore, fluctuating foreign exchange rates remain a concern for Prestige Consumer, as it generates a substantial amount of its total revenues from international business. This could result in unfavorable price increases for the company’s products or lead to higher costs for certain products purchased from its foreign third-party manufacturers.
A Look at PBH’s Estimates
The Zacks Consensus Estimate for fiscal 2025 EPS has moved north 0.4% to $4.52 in the past 30 days.
Prestige Consumer has an earnings yield of 5.3% compared with the industry’s 0.3%.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Masimo (MASI - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health has an earnings yield of 8.2%, well ahead of the industry’s 1.2%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 27.06%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo, presently carrying a Zacks Rank #1, has an earnings yield of 2.5%, well ahead of the industry’s -3.6%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 14.4%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term earnings growth rate of 10.7% compared with the industry’s 9.4%. Shares of the company have rallied 12.1% against the industry’s 2.3% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.